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ABSTRACT: Widespread exposure to the endocrine
active compound, bisphenol A (BPA), is well docu-
mented in humans. A growing body of literature sug-
gests adverse health outcomes associated with vary-
ing ranges of exposure to BPA. In the current study,
we measured the internal dose of free BPA and con-
jugated BPA and evaluated gene expression of bio-
transformation enzymes specific for BPA metabolism
in 50 first- and second-trimester human fetal liver sam-
ples. Both free BPA and conjugated BPA concentrations
varied widely, with free BPA exhibiting three times
higher concentrations than conjugated BPA concen-
trations. As compared to gender-matched adult liver
controls, UDP-glucuronyltransferase, sulfotransferase,
and steroid sulfatase genes exhibited reduced expres-
sion whereas β-glucuronidase mRNA expression re-
mained unchanged in the fetal tissues. This study pro-
vides evidence that there is considerable exposure to
BPA during human pregnancy and that the capacity
for BPA metabolism is altered in the human fetal liver.
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INTRODUCTION
Bisphenol A (BPA) is incorporated into polycar-
bonate plastic and epoxy resin for use in a variety of
products for its desirable commercial properties in-
volving transparency, malleability, and high impact
strength [1]. BPA is commonly found in products such
as dental sealants, water bottles, canned food items, and
thermal receipt papers [2–5]. The leaching of BPA from
consumer products presents many opportunities for
human exposure via inhalation, ingestion, and dermal
routes. Hence, human exposure to BPA is widespread,
and several studies have reported detectable levels of
total urinary BPA in a majority of individuals in popu-
lations around the world, including the United States,
China, and Korea [6, 7]. While most human biomoni-
toring studies report total BPA levels in urine, free BPA
and BPA metabolite measurements in tissue are neces-
sary to assess the relationships between internal dose
and adverse health outcomes.
Animal studies suggest that BPA exposures, even
at low doses well below the established U.S. Envi-
ronmental Protection Agency (EPA) reference dose of
50 μg/kg BW/day, are associated with breast and
prostate cancer and reproductive and behavioral ab-
normalities [8, 9]. Among the limited studies focus-
ing on BPA exposure on human health, increased BPA
levels were correlated with cardiovascular disease, de-
creased semen quality, altered childhood behavior, and
recurrent miscarriages [10–13]. BPA can mimic or an-
tagonize endogenous hormones, and subsequently per-
turb endocrine function, by binding weakly to sev-
eral steroid receptors including the estrogen receptors
(ER α and β) and thyroid hormone receptor [14–16].
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BPA has a strong binding affinity for the transmem-
brane ER, G protein-coupled receptor 30 (GPR30), and
the orphan nuclear receptor, estrogen-related receptor
gamma (ERRγ ) [17,18]. BPA can also activate transcrip-
tion factors, such as peroxisome x receptor (PXR) and
the aryl hydrocarbon receptor (AhR), which are often
involved in cross-talk with steroid receptors [19, 20].
Many of these receptors play an important role in gene
regulation, suggesting that BPA may influence nor-
mal differentiation and maturation processes especially
during embryonic and fetal development.
While the debate on human BPA exposure–disease
relationships continues, the National Toxicology Pro-
gram declared in 2008 that there is concern for BPA
toxicity in sensitive populations such as pregnant
women and children. In adults, human pharmacoki-
netic data suggest rapid metabolism of estrogenic free
BPA into the nonestrogenic BPA glucuronide and BPA
sulfate metabolites, via UDP-glucuronyltransferase
(UGT2B15) and sulfotransferase (SULT1A1) enzymes,
followed by urinary elimination [21,22]. In human and
rodent fetuses and neonates, however, there is gener-
ally reduced or altered capacity for chemical detoxifi-
cation [23, 24], and thus, metabolism may not ensure
negligible risk in these vulnerable populations. Fur-
thermore, β-glucuronidase (GUSB) and steroid sulfa-
tase (STS), enzymes that catalyze the breakdown of
inactive BPA metabolites to free BPA, have been de-
tected in mammalian placenta [25, 26], and a number
of studies report detectable levels of active BPA in the
human placenta and amniotic fluid [27–29], indicating
the potential for dysregulation of important biological
processes necessary for fetal development and disease
progression later in life.
In this study, first- and second-trimester
human liver specimens were analyzed using high-
performance liquid chromatography coupled with
tandem mass spectrometry (HPLC-MS/MS) for
endogenous BPA concentrations to assess in utero
exposure. To assess the ability of the fetus to detoxify
BPA, tissue-specific BPA concentrations were com-
pared to expression of biotransformation enzyme
isoforms specific to BPA metabolism. Furthermore, we
compared BPA dose and mRNA expression between
fetal and adult liver specimens.
MATERIALS AND METHODS
Tissue Samples
Human fetal liver samples, ranging from gesta-
tional day 74–120, were obtained from the NIH-funded
University of Washington Birth Defects Laboratory fe-
tal tissue bank (2R24 HD000836-47). These healthy
tissue specimens were collected from volunteers un-
dergoing elective pregnancy termination during the
first or second trimester of pregnancy. After surgery
and proper consent for donation, organs were flash-
frozen and subsequently stored in polycarbonate-free
polypropylene tubing at –80◦C, prior to shipment to
the University of Michigan (UM) on dry ice. From the
date of receipt at UM to BPA processing, only one sam-
ple was stored at –80◦C for 2 years (>75% stored for
<1 year). BPA in urine samples has previously been
assessed for degradation in –80◦C storage [30] and
thus is not expected to be a considerable limitation
in our study. No significant correlation was observed
between time in –80◦C storage and free BPA levels
(R2 < 0.03).
Other than gestational age, and occasionally sex
and race, no identifying information about the clin-
ical samples was provided. Samples with missing
sex information (N = 10) were assayed for the Y-
chromosome specific SRY and the X-chromosome spe-
cific ATL1 genes using a nested PCR analysis as de-
scribed previously, with slight modifications [31]. As
controls, healthy frozen adult liver samples were pro-
cured from Asterand (Detroit, MI). These normal adult
liver specimens, belonging to one male and one female
50-year-old Caucasian subjects, were recovered
from routine autopsies, stored in polycarbonate-free
polypropylene tubing, and immediately frozen for stor-
age. The liver specimens did not exhibit any patholog-
ical characteristics.
BPA Analysis and Quality Control
Frozen liver samples were processed for quantifi-
cation of free BPA and conjugated BPA metabolites.
An average of 630 mg (between 400 and 970 mg) of
excised frozen tissue was pulverized into fine powder
using a stainless steel mortar and ceramic pestle above
liquid nitrogen and stored in a 2-mL polypropylene ep-
pendorf tube. The homogenized tissue was shipped to
the Wadsworth Center (New York State Department of
Health, Albany, NY) overnight on dry ice, where sam-
ples were processed. Homogenized liver samples were
spiked with 5 ng of the internal standard, 13C12-BPA,
and further homogenized in 5 mL of acetonitrile. The
method for the analysis of free BPA and conjugated
BPA has been previously described [32]. Briefly, tissue
samples were extracted several times with acetonitrile
and reconstituted with 10% dichloromethane in hex-
ane. Sample extract was then loaded onto a Strata NH2
cartridge (200 mg/3 cc; Phenomenex, Torrance, CA)
preconditioned with 5 mL of 80% methanol in acetone
and 5 mL of hexane. The cartridge was washed with
5 mL of hexane and eluted with 5 mL of 80% methanol
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in acetone. The eluate was concentrated to 0.5 mL
under a gentle stream of nitrogen. The resulting ex-
tract represents free BPA, whereas the residual pellet
was further processed for conjugated BPA quantifica-
tion. The pellet, after addition of 5 ng of the internal
standard and 1 mL of water, was digested in 1 mL
of 1 M ammonium acetate buffer containing 2 μL/mL
β-glucuronidase (with 0.6% sulfatase activity; from He-
lix pomatia, 145,700 unit/mL; Sigma, St Louis, MO) at
37◦C for 12 h. This conjugated BPA fraction was ex-
tracted thrice with ethyl acetate. The sample extract was
concentrated to near dryness, reconstituted with 10%
dichloromethane in hexane, and purified by passing
through the Strata NH2 cartridge as described above.
The final eluate was concentrated to 0.5 mL.
BPA and 13C12-BPA detection from both extracts
was quantified using a high-performance liquid chro-
matography (HPLC) coupled with API 2000 elec-
trospray triple-quadrupole mass spectrometer (ESI-
MS/MS; Applied Biosystems, Foster City, CA), and
modified from a protocol published previously [33].
Ten microliters of each extract was injected onto an ana-
lytical column, set at 25◦C and a flow rate of 300 μL/min
with the mobile phase comprising of varying methanol
and water mixtures (25–99% methanol gradient). In-
strument parameters were as follows: MS/MS was set
to electrospray negative mode, cone voltage set at –30
V, collision energy set at –25 V, capillary voltage set
at –4.5 KV, and desolvation temperature set at 400◦C.
For detection, transitions were monitored at 227 > 212
for BPA and 239 > 224 for 13C12-BPA using multiple
reaction monitoring (MRM).
Several quality assurance and quality control mea-
surements were taken to assure the validity of the ana-
lytical technique. Selected sample matrices were spiked
with BPA standards and then passed through the en-
tire analytical procedure. Results indicated an average
recovery of 104% (90–120%) for spiked BPA and 85%
(65–120%) for spiked 13C12-BPA. An external calibration
curve was prepared by injecting standards at varying
concentrations (10 μL of 0.05–100 ng/mL), resulting in
a calibration coefficient >0.99. In addition, a procedural
blank (water) was analyzed between every 10 samples
that were analyzed. To prevent contamination, only
polypropylene or BPA-free supplies were used during
sample processing. Furthermore, BPA-free water was
stored at –80◦C and then pulverized over the frozen
mortar and pestle apparatus, similar to the process
described above, to assess contamination introduced
during homogenization. Free BPA and conjugated BPA
concentrations were both below the limit of quantita-
tion (LOQ) of 0.1 ng/g in controls and blanks. For data
analysis, liver BPA concentrations below the LOQ were
assigned a value of 0.071 ng/g, which was estimated
by dividing the LOQ by the square root of 2.
RNA Extraction and cDNA Synthesis
Total RNA, in addition to genomic DNA and to-
tal protein, was purified from frozen liver tissue using
the AllPrep DNA/RNA/Protein kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Be-
fore extraction, 10–20 mg of tissue was added to a 2-mL
round bottom microcentrifuge tube containing 600 μL
of Buffer RLT with 1% β-mercaptoethanol and a 5-mm
stainless steel bead, and subsequently homogenized
twice for 2 min at 20 Hz in the TissueLyser II (Qia-
gen). RNA quality and quantity was assessed using
the Nanodrop 2000 spectrophotometer (Thermo Scien-
tific, Wilmington, DE) and Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
To generate complementary DNA for each sam-
ple, approximately 1 μg of total RNA template was
used with the iScript cDNA synthesis kit (Bio-Rad, Her-
cules, CA) following the manufacturer’s protocol. The
thermocycler settings for cDNA synthesis required in-
cubation at 25◦C for 5 min, 42◦C for 60 min, and 90◦C
for 5 min.
Primer Design and Real-time Quantitative
PCR
Primer pairs for real-time quantitative polymerase
chain reaction (RT-qPCR) were designed for four genes
related to BPA metabolism using GenScript Real-Time
PCR (TaqMan) Primer Design Tool (GenScript, Pis-
cataway, NJ). The final UGT2B15 primer sequence
was obtained from the Harvard Primer Bank. The
primers for human liver reference genes, GAPDH, UBC,
and B2M were similarly designed using GenScript.
All RT-qPCR primers (Table 1) were verified using
Primer BLAST (www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome) and chosen
avoiding sequence alignment over polymorphisms or
multiple binding sites. Most primers span introns or
bridge exon–exon junctions, resulting in unique am-
plicons 50–200 base pairs long. All primer sets were
tested for PCR efficiency using 10-fold serial dilutions
of a standard template. Primers with the best standard
curve slope and R2 values (>0.97) were chosen as the
final RT-qPCR assay.
Template amplification was set up in a 25-μL reac-
tion for RT-qPCR using the iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA). Each reaction, containing 2 μL
of 10-fold diluted cDNA template and 100 nM primer
concentration, was carried out in triplicate on a C100
Thermal Cycler with a CFX96 Real-Time head (Bio-
Rad). Each 96-well plate contained no template controls
for individual primer sets as well as plate control sam-
ples to adjust for interplate variability. RT-qPCR cycle
parameters were set to 95◦C for 3 min, and 40 cycles of
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TABLE 1. RT-qPCR Primers for BPA Biotransformation Analysis
GenBank Amplicon
Gene Type Gene Full Name Number Strand Primers (5’ to 3’) Tm (◦C) Size
Metabolism UGT2B15a UDP-glucuronosy-
ltransferase
NM_001076 Forward CCAACCAATGAAGCCCCTG 60.7 94
Reverse GTTGTGAGCTGCGACTCGAA 62.7












NM_002046 Forward CATCAATGGAAATCCCATCA 59.1 90
dehydrogenase
Reverse GACTCCACGACGTACTCAGC 58.5




NM_004048 Forward TCGCTCCGTGGCCTTAGCTG 58.9 161
Reverse CAATGTCGGATGGATGAAACCCAG 56.1
aPrimer sequence from Harvard Primer Bank. All other primers were designed by GenScript.
95◦C for 10 s and 55◦C for 30 s, followed by 95◦C for 10
s and 65◦C for 5 s.
The average threshold cycle (C(t)) from triplicate
runs was calculated for individual genes using the CFX
Manager Version 1.6 software (Bio-Rad). An interrun
calibration using the plate controls automatically ad-
justed data points between plates. For normalized ex-
pression, the software takes the C(t) for each gene and
then normalizes the values to the average C(t) of the en-
dogenous reference genes, GAPDH, UBC, and B2M. Re-
sults are reported as normalized fold expression change
(2−C(t)) with standard error of the mean. The final
normalized fold change reported represents fetal ex-
pression relative to expression in a gender matched
adult control, where fold change equals one.
Statistical Analysis
Distribution of BPA in liver tissue was examined
and did not appear to be normal. Free BPA, conju-
gated BPA, and total BPA (ng/g wet weight) con-
centrations were presented as percentiles, geometric
means, and variances. Bivariate nonparametric tests
(Wilcoxon rank sum and Spearman correlation) were
used to analyze free BPA and conjugated BPA concen-
trations with covariates such as sex and gestational
age. Similar bivariate analyses were conducted sepa-
rately with the primary predictors: mRNA expression
of UGT2B15, GUSB, SULT1A1, and STS. Simple and
multiple linear regression models, in which BPA con-
centration outcomes were log transformed, were tested
to assess the relationship between BPA tissue concen-
trations and gene expression. Each of the four genes
was individually analyzed with free BPA in a simple
linear regression model. Regression models were not
analyzed for conjugated BPA given that the exact BPA
glucuronide and BPA sulfate metabolite composition
was unknown. In the multiple linear regression mod-
els, gene expression and free BPA were analyzed after
adjusting for gestational age, as a confounder, and sex,
as an effect modifier. Regression coefficients (β) were
analyzed and calculated as percentage change [100(eˆβ
–1)] with p values <0.05 considered to be statistically
significant. All statistical analyses were conducted us-
ing the stats and epicalc packages in R (version 2.14.2;
The R Foundation for Statistical Computing 2012).
RESULTS
In the adult liver controls, the concentrations of
conjugated BPA were both <LOQ, whereas the con-
centrations of free BPA were <LOQ and 0.38 ng/g wet
weight (Supplementary Table 1 in the Supporting In-
formation). Greater than 70% of the 50 fetal liver sam-
ples, however, contained detectable levels of free BPA
and conjugated BPA, ranging from <LOQ to 50.5 ng/g
(geometric mean: 2.26 ng/g) and <LOQ to 49.5 ng/g
(geometric mean: 0.65 ng/g), respectively (Table 2 and
Supplementary Table 1 in the Supporting Information).
The majority (78%) of samples exhibited a free BPA to
conjugated BPA ratio greater than 1, with a mean of
6.91 and median of 3.75, across all gestational age and
sex (Supplementary Table 1 in the Supporting Informa-
tion). No significant differences in free BPA (p value:
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LOQa (%) Min 10th 25th 50th 75th 90th Max
Geometric
Mean (GSD)
Free 88 <LOQ <LOQ 0.90 2.99 6.45 26.1 50.5 2.26 (6.26)
Conjugated 72 <LOQ <LOQ <LOQ 0.63 2.04 8.00 49.5 0.65 (6.15)
Total <LOQ <LOQ 1.18 3.44 12.1 35.7 96.8 2.92 (6.89)
a LOQ is 0.1 ng/g.
FIGURE 1. Liver tissue free BPA levels are associated with gesta-
tional age but not sex. (A) A significant positive correlation between
free BPA levels and gestational age is observed (overall R2: 0.316 and
p value: 0.025). When the exposure-age correlation was stratified by
sex, no significant differences were observed (female R2: 0.333 and
p value: 0.120; male R2: 0.345 and p value: 0.078). (B) A marginally
significant trend was found between conjugated BPA and gestational
age (overall R2: 0.269 and p value: 0.059; female R2: 0.183 and p value:
0.404; male R2: 0.062 and p value: 0.062).
0.675) or conjugated BPA (p value: 0.976) concentra-
tions appeared between male and female specimens.
After assessing BPA concentrations over developmen-
tal time span (Figure 1), gestational age was found to
be significantly correlated with free BPA (R2 = 0.316;
p value: 0.025) but only marginally significant with
conjugated BPA (R2 = 0.267; p value: 0.059) across all
samples.
In general, mRNA expression of UGT2B15 and
SULT1A1 was significantly reduced (p values: 0.039
and 0.044, respectively), whereas STS expression was
marginally reduced (p value: 0.054) in fetal liver com-
pared to adult liver samples. Furthermore, normal-
ized mRNA expression was significantly higher in
male compared to female fetal livers, especially for
UGT2B15, SULT1A1, and STS expression (p value:
<0.005 for all three genes; Figure 2). GUSB displayed
no significant difference in expression between fetal
and adult liver samples (p value: 0.197). There were
no significant correlations between expression of the
four BPA biotransformation genes and gestational age
(p value: >0.200 for all associations).
The association between fetal liver free BPA con-
centrations and expression of candidate genes related
to BPA metabolism was assessed using linear regres-
sion. No significant associations were observed be-
tween free BPA concentration and expression levels in
simple regression modeling (UGT2B15 p value: 0.441,
SULT1A1 p value: 0.914, GUSB p value: 0.477, and STS
p value: 0.753). The correlation between free BPA and
many of the gene expression profiles, however, differed
between male and female liver specimens, suggesting
that sex may act as a potential effect modifier. There-
fore, in the final model, an interaction term between
sex and expression was added along with adjustment
for gestational age. There were no significant relation-
ships between free BPA tissue concentration and indi-
vidual biotransformation gene expression values ad-
justing for gestational age, sex, and their interaction
(p value: >0.500 for all associations).
DISCUSSION
Studies reporting internal dose of BPA in hu-
man tissues at vulnerable developmental stages are
presently lacking. When we measured endogenous
BPA concentrations in human fetal liver, detectable lev-
els of free and conjugated species were found, rang-
ing from <LOQ to 50 ng/g wet weight (parts per
billion). Comparable concentrations of free BPA have
been previously reported in 49 term placentas collected
from Spanish women (<LOQ- 22.2 ng/g), 248 amniotic
fluids from second-trimester Japanese women (<LOQ-
5.62 ng/mL), and 28 fetal livers from a Canadian popu-
lation (<LOQ- 37.7 ng/g) [27,28,34]. Often, these stud-
ies only quantify free BPA or total BPA, and the LOQs
are higher than 0.1 ng/g.
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FIGURE 2. Biotransformation gene expression levels are associated
with sex. Boxplots represent sex stratified biotransformation enzyme
expression in fetal livers compared to adult livers, normalized to
onefold change for each gene. (A) Fetal liver expression of UGT2B15
is significantly reduced compared to adults (overall p value: 0.039).
Here, normalized male expression is significantly higher than female
expression (p value: < 0.001). GUSB, however, does not exhibit signifi-
cant difference in expression between fetal and adult samples (overall
p value: 0.197). Also, there is no significant difference in normalized
expression between male and female (p value: 0.463). (B) Fetal liver
expression of SULT1A1 is also significantly reduced compared to
adults (overall p value: 0.044). The difference in STS expression be-
tween fetal compared to adult samples is only marginally significant
(overall p value: 0.054). Normalized male expression is significantly
higher than female expression in both SULT1A1 and STS (p value:
0.001 and p value: <0.001), respectively).
A higher free BPA to conjugated BPA ratio in this
sample population is especially notable, given that
free BPA normally represents 10–30% of total BPA
in adult urinary excretions [35, 36]. The discrepancy
in our clinical samples may be attributed to varying
metabolic potential across tissues and time points, or
as a result of contamination during sample process-
ing. Several experimental precautions were taken, in-
cluding use of polycarbonate-free equipment and neg-
ative controls throughout processing. Any exogenous
BPA introduced during tissue procurement likely af-
fected all samples; however, the wide range of free BPA
and <LOQ levels observed implies otherwise. Further-
more, a recent study examining BPA in second- and
third-trimester amniotic fluid from American women
found that free BPA accounted for more than 80% of
total BPA levels [37].
The biotransformation system undergoes signifi-
cant changes during hepatic maturation, resulting in
differential response to xenobiotic chemicals. Hepatic
mRNA and protein expression of 13 UGT genes, in-
cluding UGT2B15, were not detectable in the fetus and
were reduced in children compared to adults [38]. In
our larger collection of samples, we also found sig-
nificantly reduced mRNA expression of UGT2B15 in
fetal liver. While fetal GUSB did not show differen-
tial expression, STS exhibited significantly reduced ex-
pression compared to adult livers, as supported by
other studies [39–41]. Hepatic SULT genes, especially
SULT1A1, often exhibit protein expression levels that
are equivalent to adult levels [42,43]. Although we ob-
served reduced mRNA expression of SULT1A1 in fetal
liver, there was wide variability in our samples. Future
studies can be improved by increasing the number of
adult liver controls to account for intersubject variabil-
ity resulting from not only differential exposure but
also genetic variation contributing to altered xenobi-
otic metabolism. Furthermore, integration of gene on-
togeny with genetic variants involved in differential
BPA metabolism, such as the UGT2B15 D85Y substitu-
tion [44], among others, will be necessary for complete
understanding of altered BPA metabolism in human
fetal samples.
When the relationship between biotransformation
gene expression and free BPA concentration was exam-
ined, no significant correlations were observed. In ad-
dition to small sample size, several reasons may help
explain the lack of association, even after adjustment
for gestational age and gender. First, the mRNA lev-
els quantified in these first- and second-trimester liver
samples may not be a good proxy for measuring func-
tional activity of biotransformation enzymes at this
particular window of development. Thus, experiments
that assess protein activity of BPA biotransformation
enzymes in fresh human tissue will be valuable. Sec-
ond, there is also the possibility that, despite experi-
mental precautions described above, free BPA was in-
troduced exogenously during sample procurement and
this contamination may have negated any true asso-
ciations between expression and exposure. Therefore,
the optimal regression model should evaluate biotrans-
formation gene expression with their respective BPA
species. Future analyses will require separate charac-
terization of both BPA glucuronide and BPA sulfate in
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tissue. Finally, the high free BPA to conjugated BPA
ratio observed may also be a result of deconjugation
in the placenta or differential exposure from physio-
logical changes occurring in the mother during preg-
nancy [40, 45]. To assess BPA fate throughout human
pregnancy, investigation of BPA metabolism and trans-
port in the placenta, maternal liver, and fetal liver is
required.
As is true in many human studies, bioethical issues
and the paucity of appropriate samples limit our abil-
ity to fully comprehend the role of BPA biotransforma-
tion during this sensitive window of development. This
study is one of the first of its kind to investigate both
BPA conjugating and deconjugating enzyme gene ex-
pression in relation to endogenous BPA exposure in the
developing human fetus. Characterizing biotransfor-
mation gene ontogeny with BPA exposure from early
gestation to birth will enhance our understanding of
BPA fate and subsequent health effects.
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